REPORT SCOPE
INTRODUCTION
STUDY GOAL AND OBJECTIVES
BCC’s goal for this study is to determine the specific applications and forecast global market demand for synthetic biology products over a 5-year period from 2011 to 2016. Our particular interest is to characterize and quantify the synthetic biology products market potential by product type and end use market segments. We also analyze the synthetic biology industry structure, competitors, and intellectual property landscape.
Synthetic biology markets reviewed in this report include enabling products, biologic components, integrated systems, and enabled products.
Our key objective is to present a comprehensive analysis of the emerging synthetic biology industry, with an emphasis on products and technologies that are commercially important in the 2011-to-2016 time period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the synthetic biology industry.
The study will be particularly useful to companies supplying synthetic genes, oligonucleotides, DNA sequencing instruments, cell culture media, biofuels, specialty chemicals, pharmaceuticals, vaccines, microfluidics, and life sciences tools.
REASONS FOR DOING THE STUDY
Synthetic biology is a rapidly emerging biotechnology discipline with a wide range of applications. Despite its emerging status, synthetic biology provides a significant number of near-term commercial opportunities, and the list of new products and applications is continuously growing. These applications include specialty chemicals, enzymes, synthetic genes and other DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.
It is important for companies in industries affected by the developments in synthetic biology to sort through the many potential applications to identify near-term commercial opportunities for product development focus. This report allows companies to prioritize product opportunities, establishing a solid framework for strategic planning.
Synthetic biology encompasses a wide range of industries including life science tools, biotechnology, pharmaceuticals, diagnostics, energy, and chemicals. Because of its wide scope, synthetic biology plays an important role in the future of the industrial economy.
Ongoing advances in enabling technologies such as DNA synthesis and sequencing, specialty media, and bioinformatics, as well as a need for renewable feedstocks, are driving the growth of synthetic biology. Rapid developments in these multidisciplinary fields promise to advance the synthetic biology industry and create unique market opportunities. This report analyzes these trends and their impact on the future markets for synthetic biology products.
Based on these market and technology dynamics, it is especially timely to examine the current and future synthetic biology markets.
INTENDED AUDIENCE
We have compiled a study of existing and future synthetic biology products and technologies that will be commercially important in the main end user segments of life science research, pharmaceuticals, diagnostics, energy, chemicals, and agriculture.
We present markets by end use segment (R&D, diagnostics/pharmaceuticals, energy, chemicals, and agriculture) and by product type (enabling products, biologic components, integrated systems, and enabled products). Key market segments are covered, including synthetic genes, chassis organisms, biofuels, specialty chemicals, and pharmaceuticals.
We analyze synthetic biology technologies, growth driving forces, market applications, industry structure and competitive dynamics, companies and industry alliances, future market potential, and product sales forecasts for the period 2011 through 2016. We project the future use of synthetic biology products in the main end user segments and by product type.
This report will be of particular interest to pharmaceuticals, chemicals, enzymes, energy, agricultural, biotechnology, and bionanobiotechnology companies, as well as suppliers of genomics tools, DNA synthesis, and DNA sequencing products. It will also be of high interest to professionals within governments and regulatory agencies to understand the scope and pace of synthetic biology technologies as they reach the market.
SCOPE AND FORMAT
The study’s scope includes core synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, specialty media, bioinformatics), and enabled technologies (biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture) that are already commercial or forecast to be commercialized within the next 5 years.
We analyze key synthetic biology technologies and products to determine present and future market status, and forecast growth from 2011 through 2016. We also discuss strategic alliances, industry structures, competitive dynamics, patent strategy, and market driving forces.
BCC examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceutical companies, biofuels, and specialty chemicals. The role of key strategic alliances from 2009 through 2011 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, and chassis organisms are analyzed, as well as metabolically-engineered factories for producing synthetic fuels and specialty chemicals. The main companies in these fields are highlighted.
METHODOLOGY
BCC surveys key users and producers in each of the end user market segments and technology fields that will be commercially important during the next 5 years. Discussions with industry thought leaders, as well as secondary market research was performed.
Based on our analysis, we project the future applications of synthetic biology technologies in the major end user market segments and by technology type, and forecast sales revenues for 2011 through 2016.
INFORMATIION SOURCES
BCC surveyed leading synthetic biology, biotechnology, pharmaceutical, chemical, and energy companies to obtain data for this study. Included were life science research tools, drug, biotechnology, DNA synthesis and sequencing, and microfluidics firms, as well as leading life science research institutions. We also obtained inputs from leading academic and industry thought leaders. Data from secondary sources included industry, trade, and government publications.
ANALYST CREDENTIALS
The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; and Biologic Imaging Reagent: Future Technologies and Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Subscribe to any of BCC Research’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for its well-known conferences.
- Request additional information on any BCC research product.
- Take advantage of special offers.
DISCLAIMER
This publication provides informative material of a professional nature. It does not constitute managerial, legal, or accounting advice, nor should it serve as a corporate policy guide or an endorsement of any given product or company. This information is intended to be as accurate as possible at the time it was written and was undertaken on a best-effort basis. The views expressed are those of the author and do not make any warranty, express or implied, for the accuracy, completeness, or usefulness of the information, or for the interpretation of data or its use by others. Projections involve risks and uncertainties that include but are not limited to technical risks associated with technology development, government regulatory approvals, and access to capital. The author assumes no responsibility for any losses or damages that may result from one’s reliance on this material.
